The LDN Shop
Visit our e-commerce website for Conferences, Webinars, Medical Membership, eBooks etc
Paul Anderson, NMD - Case Studies (2017 Conference) (LDN, low dose naltrexone)
The first case is an oncology patient, a 47 year old female with colorectal cancer. This lady presented herself while halfway through standard cancer treatment. Dr Anderson added many adjunct therapies as well as Low Dose Naltrexone and the patients tumour markers reduced for the first time.
Dickson Chemist developed a new formulation of LDN which will hopefully improve the outcomes for patients. This new formulation is a more concentrated liquid in the form of drops which are administered under the tongue and absorbed directly from the mucosal lining of the mouth. This sublingual route produces a more rapid absorption bypassing the liver and digestive tract. There are several potential advantages to this, the drug may be more effective and will not be affected by the presence of food stuffs or the hostile environment of the gut.